Allogene Therapeutics, Inc. (ALLO) vs CytomX Therapeutics, Inc. (CTMX)

A side-by-side comparison of Allogene Therapeutics, Inc. and CytomX Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ALLO vs CTMX

growth of $100 · dividends reinvested · last 8y
ALLO -94.0% (-29.6%/yr)CTMX -84.6% (-20.9%/yr)CTMX compounded faster over this window
050100150200Start $1002020202220242026$6$15
ALLO CTMX

ALLO vs CTMX: by the numbers

  • •CTMX is the larger company ($562M vs $518M market cap).
  • •Both run net losses; CTMX's is the smaller (-435.21% vs -3566.68% net margin).
  • •CTMX grew revenue faster over the past five years (2.18% vs -34.47% CAGR).

Metrics side by side

Valuation

MetricALLOCTMX
P/S ratio111.5830.69
P/B ratio1.191.86

Profitability

MetricALLOCTMX
Gross margin0.00%98.63%
Operating margin0.00%-29.35%
Net margin-3566.68%-435.21%
ROE-37.94%-26.37%
ROIC-34.79%-25.42%

Growth (annualized)

MetricALLOCTMX
Revenue CAGR (5Y)-34.47%2.18%
Total return CAGR (5Y)-42.72%-12.01%

Frequently asked

Which has grown faster, ALLO or CTMX?
Over the past five years, CTMX grew revenue faster — ALLO at a -34.47% CAGR versus CTMX at 2.18%.
How have ALLO and CTMX total returns compared?
Over the past 5 years, ALLO delivered -42.72% and CTMX delivered -12.01% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.